SECARE Stock Overview
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr86.92|
|52 Week High||kr159.00|
|52 Week Low||kr67.56|
|1 Month Change||-6.11%|
|3 Month Change||-22.32%|
|1 Year Change||-10.94%|
|3 Year Change||452.93%|
|5 Year Change||1,624.60%|
|Change since IPO||2,314.44%|
Recent News & Updates
|SECARE||SE Pharmaceuticals||SE Market|
Return vs Industry: SECARE exceeded the Swedish Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: SECARE exceeded the Swedish Market which returned -23.6% over the past year.
|SECARE Average Weekly Movement||9.4%|
|Pharmaceuticals Industry Average Movement||9.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in SE Market||12.2%|
|10% least volatile stocks in SE Market||4.7%|
Stable Share Price: SECARE is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: SECARE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff powder cat; ProDen PlaqueOff dental bones for dogs; ProDen PlaqueOff mini dental care bones, a chewy bone for smaller dogs; and ProDen PlaqueOff soft chews for dogs and cats. The company also provides dietary supplements for cats, dogs, and horses under the NutriScience brand, such as Glucosamine and Stomax used to renew joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid for joints and mobility; KalmAid, which helps to calm nervous dogs; and OmegaAid and RevitalAid, a feed supplement used for healthy skin and coat.
Swedencare Fundamentals Summary
|SECARE fundamental statistics|
Is SECARE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SECARE income statement (TTM)|
|Cost of Revenue||kr507.23m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 28, 2022
|Earnings per share (EPS)||0.36|
|Net Profit Margin||5.61%|
How did SECARE perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is SECARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SECARE?
Other financial metrics that can be useful for relative valuation.
|What is SECARE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SECARE's PS Ratio compare to its peers?
|SECARE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
KARO Karo Pharma
CALTX Calliditas Therapeutics
IRLAB A IRLAB Therapeutics
Price-To-Sales vs Peers: SECARE is expensive based on its Price-To-Sales Ratio (13.5x) compared to the peer average (11.8x).
Price to Earnings Ratio vs Industry
How does SECARE's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Sales vs Industry: SECARE is good value based on its Price-To-Sales Ratio (13.5x) compared to the Swedish Pharmaceuticals industry average (15.2x)
Price to Sales Ratio vs Fair Ratio
What is SECARE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13.5x|
|Fair PS Ratio||12.6x|
Price-To-Sales vs Fair Ratio: SECARE is expensive based on its Price-To-Sales Ratio (13.5x) compared to the estimated Fair Price-To-Sales Ratio (12.6x).
Share Price vs Fair Value
What is the Fair Price of SECARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SECARE (SEK86.92) is trading below our estimate of fair value (SEK185.31)
Significantly Below Fair Value: SECARE is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: SECARE is poor value based on its PEG Ratio (6.5x)
Discover undervalued companies
How is Swedencare forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SECARE's forecast earnings growth (36.9% per year) is above the savings rate (0.3%).
Earnings vs Market: SECARE's earnings (36.9% per year) are forecast to grow faster than the Swedish market (9.8% per year).
High Growth Earnings: SECARE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SECARE's revenue (21.5% per year) is forecast to grow faster than the Swedish market (5.6% per year).
High Growth Revenue: SECARE's revenue (21.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SECARE's Return on Equity is forecast to be low in 3 years time (5.7%).
Discover growth companies
How has Swedencare performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SECARE has high quality earnings.
Growing Profit Margin: SECARE's current net profit margins (5.6%) are lower than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: SECARE's earnings have grown significantly by 31.5% per year over the past 5 years.
Accelerating Growth: SECARE's earnings growth over the past year (69.1%) exceeds its 5-year average (31.5% per year).
Earnings vs Industry: SECARE earnings growth over the past year (69.1%) exceeded the Pharmaceuticals industry 17.9%.
Return on Equity
High ROE: SECARE's Return on Equity (0.9%) is considered low.
Discover strong past performing companies
How is Swedencare's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SECARE's short term assets (SEK945.7M) exceed its short term liabilities (SEK495.3M).
Long Term Liabilities: SECARE's short term assets (SEK945.7M) do not cover its long term liabilities (SEK2.3B).
Debt to Equity History and Analysis
Debt Level: SECARE's net debt to equity ratio (16.8%) is considered satisfactory.
Reducing Debt: SECARE's debt to equity ratio has reduced from 38.3% to 21.1% over the past 5 years.
Debt Coverage: SECARE's debt is not well covered by operating cash flow (11.7%).
Interest Coverage: SECARE's interest payments on its debt are well covered by EBIT (5.8x coverage).
Discover healthy companies
What is Swedencare current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SECARE's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.67%).
High Dividend: SECARE's dividend (0.23%) is low compared to the top 25% of dividend payers in the Swedish market (5.41%).
Stability and Growth of Payments
Stable Dividend: SECARE is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.
Growing Dividend: SECARE is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: SECARE is not paying a notable dividend for the Swedish market.
Cash Payout to Shareholders
Cash Flow Coverage: SECARE is not paying a notable dividend for the Swedish market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hakan Lagerberg (53 yo)
Mr. Hakan Lagerberg serves as an Independent Director at Polygiene Group AB (formerly known as Polygiene AB (publ.)) since May 17, 2019. He serves as Chief Executive Officer at Swedencare AB (publ) since J...
CEO Compensation Analysis
Compensation vs Market: Hakan's total compensation ($USD209.75K) is below average for companies of similar size in the Swedish market ($USD972.85K).
Compensation vs Earnings: Insufficient data to compare Hakan's compensation with company performance.
Experienced Management: SECARE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: SECARE's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SECARE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 50%.
Swedencare AB (publ)'s employee growth, exchange listings and data sources
- Name: Swedencare AB (publ)
- Ticker: SECARE
- Exchange: OM
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr13.743b
- Shares outstanding: 158.11m
- Website: https://www.swedencare.se
Number of Employees
- Swedencare AB (publ)
- Medeon Science Park
- Skåne County
- 205 12
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.